It appears that someone again is picking up a lot of shares. We did break through the 1.23 key resistance level, and the next major resistance level is 1.40. With some additional up volume, we could possibly see 1.25 taken out, and from there 1.30 should be on the horizon. Overall, the trend line is heading north. GLTA!
Sentiment: Strong Buy
As you know PEG-SN38 was developed to be a multi-dimensional inhibitor, whereby it possesses broad based applications. Where I believe it could make the biggest impact is combating metastatic breast cancer, although, reading through the abstracts PEG-SN38 has shown promising clinical data combating Pediatric Neuroblastoma.
Overall, the royalty revenue stream potential from PEG-SN38 could be significant for Enzon. PEG-SN38 is now in 2/3 Phase Trials, which was launched in Q1 2014 - it's very possible that preliminary data could be released this quarter. GLTY!
Sentiment: Strong Buy
I'll answer my own question,,, Rev from BEL-0222 could potentially exceed 60 Million annually,
JUST FOR PEG-SN38 existing agreement with Hisun, We also get a piece of any new agreements
FROM 8K: ASSET SALE TO BELROSE
"The aggregate upfront consideration for the assets is $800,000, $700,000 of which the Company received at closing and $100,000 of which was placed into escrow and is to be released to the Company if the Company consummates the sale of its right, title and interest in the LNA Technology platform and related assets to Belrose. The Agreement also entitles the Company to receive from Belrose additional potential payments, including a share of net revenues that may be received from Hisun related to PEG-SN38 rights in China as well as a share of other potential partnering revenues. The achievement of any of these potential payments is uncertain. "
PEG-SN38 is very promising and in Phase III,,,
Did Enzon Retain Royalty rights to the PEG phase III ready trials sold to Belrose,
FROM the 10Q:
"We are party to license agreements whereby we may receive royalties from products subject to
If Approved, BEL-0222 is expected to replace Pizer's irinotecan,,, 900 MILLION ANNUAL MARKET,,
@7.5% ENZONS CUT would be potentially,,, 67 Million in annual Rev....
patents, tax credits have value..it is not zero. Institutions and powerful investors will maximize the value of the assets.
sounds too good to be true...... i think to buy is to buy and hold. if they use up all the cash to divy then what value is the buyout/
think of it this way...
You pay $1.30 for one share now, and you receive $3.00 in dividends over the next 3 years. Or between now and then, the share is bought out for anywhere between $2 to $10+ per share. Or the market sees this potential at some point and starts pricing it in more appropriately. This could happen gradually or suddenly because we are one catalyst away from going ballistic. IMO
We have what, over $40M in the bank? Our cap is $55M. Rough numbers indicate that we can reasonably and conservatively expect royalty payments of around $100M in the next three years. The company still owns patents with value. They also have valuable tax credits that can be utilized under certain circumstances, and could also have value to someone. The premise is brilliant, under the circumstances.. Minimize costs, and pass all the value back to the shareholders through divvy's, and in the end get a great share price on a buyout. on the remaining assets. The question is how soon does a potential buyer pull the trigger? Is it before or after the next divvy? In any case, it is my most humble opinion that we are in store for some nice upside.
i would hope they make some money in the interim until they pay out the dividend. buy some short term bonds at least get some interest off of it